{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:46Z","timestamp":1793316286985,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtho.2025.12.080","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:57:25Z","timestamp":1766509045000},"page":"103541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial"],"prefix":"10.1016","volume":"21","author":[{"given":"David","family":"Planchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thatthan","family":"Suksombooncharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Samol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotsawaj","family":"Runglodvatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P.L.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrina","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aumkhae","family":"Sookprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica C.","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McEwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James CH.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.12.080_bib1","unstructured":"World Health Organization. Lung cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer. Accessed September 19, 2025."},{"key":"10.1016\/j.jtho.2025.12.080_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib4","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3390\/cancers15112899","article-title":"Emerging targeted therapies in advanced non-small-cell lung cancer","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.12.080_bib5","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1200\/JCO.22.02124","article-title":"Therapy for Stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline, version 2022.2","volume":"41","author":"Owen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib6","first-page":"5238","article-title":"HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of Herceptin","volume":"9","author":"Heinm\u00f6ller","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.12.080_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2003.09.026","volume":"44","author":"Zinner","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.12.080_bib8","first-page":"4631","article-title":"The prognostic significance of HER2 overexpression in non-small cell lung cancer","volume":"31","author":"Takenaka","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2025.12.080_bib9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label Phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.12.080_bib13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.12.080_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.12.080_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.12.080_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, Phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib20","first-page":"695","article-title":"Abstract: Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1\/PD-L1 therapy (Hudson)","volume":"11","author":"Cheema","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2025.12.080_bib21","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2025.12.080_bib22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1538-7445.AM2024-1366","article-title":"Abstract: dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models","volume":"84","author":"Jenkins","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.12.080_bib23","article-title":"Abstract: 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): interim analysis of a phase Ib study","volume":"24","author":"Italiano","year":"2024","journal-title":"ESMO IOTECH"},{"key":"10.1016\/j.jtho.2025.12.080_bib24","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, Phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.12.080_bib26","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1200\/JCO.2023.41.16_suppl.9114","article-title":"Abstract: SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study","volume":"41","author":"Fang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.12.080_bib28","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO-24-02744","article-title":"Patritumab deruxtecan (HER3-DXd; MK-1022) in non-small cell lung cancer after platinum-based chemotherapy and immunotherapy","volume":"43","author":"Steuer","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.12.080_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.064","article-title":"Abstract LBA51: Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.12.080_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib33","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib34","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Abstract: Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib36","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1111\/1759-7714.13681","article-title":"Prognostic factors for survival in patients with metastatic lung adenocarcinoma: an analysis of the SEER database","volume":"11","author":"Campos-Balea","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2025.12.080_bib37","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.12.080_bib38","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"Abstract 1321MO: Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): pooled analyses from DESTINY-Lung01 and DESTINY-Lung02","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib39","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib40","article-title":"Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: current status, possible mechanisms and application prospects","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2025.12.080_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2006.12.002","article-title":"Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms","volume":"33","author":"Stewart","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2025.12.080_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2019.104290","article-title":"High expression of NFAT2 contributes to carboplatin resistance in lung cancer","volume":"110","author":"Liu","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jtho.2025.12.080_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1100","article-title":"Abstract: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced\/metastatic breast or non-small cell lung cancer (NSCLC): a phase Ib, multicenter study","volume":"38","author":"Borghaei","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.12.080_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113920","article-title":"Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer","volume":"201","author":"Tarantino","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.12.080_bib47","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.30408","article-title":"HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research","volume":"139","author":"Pietrantonio","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2025.12.080_bib48","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/cancers16050940","article-title":"ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.12.080_bib49","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/s41379-021-00880-0","article-title":"Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas","volume":"34","author":"Lin","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425030217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425030217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:23:28Z","timestamp":1778232208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425030217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1556086425030217"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.12.080","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.12.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103541"}}